Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Acorda Therapeutics Inc (ACOR)  
$0.50 0.00 (0.00%) as of 4:30 Fri 6/2


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 47,962,000
Market Cap: 24.08(M)
Last Volume: 12,631,282 Avg Vol: 9,842,189
52 Week Range: $0.502 - $0.65
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of episodic motor fluctuations, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija utilizes Co.'s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Co. also markets Ampyra (dalfampridine) extended release tablets, 10 mg for improving walking in patients with multiple sclerosis. Ampyra is marketed as Fampyra outside the U.S.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 20,156
Total Buy Value $0 $0 $0 $12,594
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 2
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-29 2023-11-28 2023-05-30 2022-05-30

   
Records found: 610
  Page 21 of 25  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Lawrence David Chief Financial Officer   •       –      –    2007-12-27 4 OE $2.60 $18,200 D/D 7,000 12,123     -
   Wasman Jane Exec VP, General Counsel & Sec   •       –      –    2007-12-21 4 AS $20.50 $49,852 D/D (2,425) 18,439     -
   Lawrence David Chief Financial Officer   •       –      –    2007-12-21 4 AS $20.50 $22,736 D/D (1,107) 5,123     -
   Lawrence David Chief Financial Officer   •       –      –    2007-12-10 4 AS $20.22 $36,718 D/D (1,800) 6,230     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-12-10 4 AS $20.21 $81,609 D/D (4,000) 31,374     -
   Cohen Ron President and CEO   •       –      –    2007-12-10 4 AS $20.22 $163,196 D/D (8,000) 140,384     -
   Lawrence David Chief Financial Officer   •       –      –    2007-11-21 4 AS $17.00 $17,201 D/D (1,003) 8,030     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-11-15 4 AS $18.10 $107,495 D/D (5,865) 35,374     -
   Wasman Jane Exec VP, General Counsel & Sec   •       –      –    2007-11-12 4 AS $18.57 $45,551 D/D (2,425) 20,864     -
   Lawrence David Chief Financial Officer   •       –      –    2007-10-23 4 AS $19.95 $20,210 D/D (1,004) 9,033     -
   Wasman Jane Exec VP, General Counsel & Sec   •       –      –    2007-10-23 4 AS $19.95 $48,813 D/D (2,425) 23,289     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-10-15 4/A S $19.91 $68,197 D/D (3,366) 36,752     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-10-15 4/A OE $2.60 $8,752 D/D 3,366 40,118     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-10-15 4 AS $19.91 $68,197 D/D (3,366) 41,239     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-10-15 4 OE $2.60 $11,666 D/D 4,487 44,605     -
   Lawrence David Chief Financial Officer   •       –      –    2007-09-26 4 AS $18.56 $37,703 D/D (2,008) 10,037     -
   Wasman Jane Exec VP, General Counsel & Sec   •       –      –    2007-09-26 4 AS $18.56 $45,583 D/D (2,425) 25,714     -
   Lawrence David Chief Financial Officer   •       –      –    2007-09-12 4 AS $15.91 $32,087 D/D (2,007) 12,045     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-09-10 4 AS $15.89 $64,382 D/D (4,000) 40,118     -
   Cohen Ron President and CEO   •       –      –    2007-09-10 4 AS $15.93 $129,105 D/D (8,000) 148,384     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-08-17 4/A S $18.00 $54,852 D/D (3,044) 40,752     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-08-17 4/A OE $2.60 $7,914 D/D 3,044 43,796     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-08-17 4 AS $18.00 $54,852 D/D (3,044) 44,118     -
   Blight Andrew Chief Scientific Officer   •       –      –    2007-08-17 4 OE $2.60 $16,666 D/D 6,410 47,162     -
   Cohen Ron President and CEO   •       –      –    2007-08-14 4 AS $16.73 $440,900 D/D (26,000) 156,384     -
  610 Records found
  Previous  20  21  22  23  24  25   
  Page 21 of 25
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us